Literature DB >> 1377311

Prospective randomized clinical trial comparing brachytherapy and laser photoablation for palliation of esophageal cancer.

D E Low1, K M Pagliero.   

Abstract

Twenty-three consecutive patients with advanced esophageal cancer were randomized to receive either endoluminal irradiation or laser photoablation treatment. Initial improvement in dysphagia scores was observed in 83% (brachytherapy) and 91% (laser). This improvement in dysphagia was maintained at 2 months in 75% (brachytherapy) and 81% (laser). Performance scores improved in 33% (brachytherapy) and 36% (laser). Both treatments were well tolerated, required a minimum of inpatient treatment time, and allowed patients to die without terminal admission to district referral centers. Retreatments were three times as common with laser therapy, but the frequency of treatment failures was equal. Minor complications, especially transient early dysphagia, was more common in the brachytherapy group, although the only major complication (perforation) occurred in the laser group. No procedure-related deaths occurred in either group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377311

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

Review 1.  Palliation in oesophageal neoplasia.

Authors:  J Bancewicz
Journal:  Ann R Coll Surg Engl       Date:  1999-11       Impact factor: 1.891

2.  Laser and brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia.

Authors:  G M Spencer; S M Thorpe; I R Sargeant; G M Blackman; J Solano; J S Tobias; S G Bown
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

Review 3.  Comparison of different treatments for unresectable esophageal cancer.

Authors:  C E Reed
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

4.  Combination of laser treatment and intraluminal radiotherapy for malignant dysphagia.

Authors:  E Shmueli; E Srivastava; P J Dawes; M Clague; K Matthewson; C O Record
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

Review 5.  Interventions for dysphagia in oesophageal cancer.

Authors:  Yingxue Dai; Chaoying Li; Yao Xie; Xudong Liu; Jianxin Zhang; Jing Zhou; Xiongfei Pan; Shujuan Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

6.  Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.

Authors:  Sang-Hee Cho; Ik-Joo Chung; Sang-Yun Song; Deok-Hwan Yang; Jeong-Rae Byun; Yeo-Kyeoung Kim; Je-Jung Lee; Kook-Joo Na; Hyeoung-Joon Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

7.  Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.

Authors:  M B Polee; W C J Hop; T C Kok; F A L M Eskens; M E L van der Burg; T A W Splinter; P D Siersema; H W Tilanus; G Stoter; A van der Gaast
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.